Please amend claim 17 as follows:

17. (Amended) A method of treating a human having a PDGF-mediated disease involving proliferation, migration or chemotaxis of smooth muscle cells, comprising administering a composition comprising [to the patient]:

a therapeutically effective dose of at least one immunoglobulin polypeptide [according to claim 1, or fragments of the immunoglobulin polypeptide] or antigen binding fragment that specifically binds to an extracellular domain of the human type beta platelet-derived growth factor receptor (β-PDGF-R) wherein specific binding of the polypeptide or fragment to the human β-PDGF-R has the following effects:

i) inhibition of PDGF BB or AB binding to the β-PDGF-R;

ii) inhibition of the PDGF-induced β-PDGF-R phosphorylation;

iii) inhibition of PDGF-induced dimerization of β-PDGF-R;

iv) inhibition of PDGF-induced mitogenesis of cells displaying the human β-PDGF-R; and

v) inhibition of PDGF-induced chemotaxis and migration of cells displaying β-PDGF-R ; and

a pharmaceutically acceptable carrier, said dose being therapeutically effective to at least partially arrest the cellular proliferation, migration or chemotaxis and their symptoms or complications.

Please add the following new claims:

--~~19.~~ The method of claim 17, wherein the PDGF-mediated disease is selected from the group consisting of:

a) restenosis;

b) vascular proliferative phenomena and fibrosis;

c) prevention of vascular narrowings in vein grafts;

d) prevention of vascular narrowings due to accelerated smooth muscle cell migration and proliferation in transplanted organs; and

e) nonvascular fibrotic processes.

~~20.~~ The method of claim 19, wherein the PDGF-mediated disease is restenosis.

~~21.~~ A method of treating a PDGF-mediated disease involving proliferation, migration or chemotaxis of smooth muscle cells, comprising the administration of a therapeutically effective dose of an anti-platelet derived growth factor (PDGF) beta receptor antibody.

~~22.~~ A method of inhibiting intimal hyperplasia in the vasculature of a mammal, comprising:

administering to said mammal a therapeutically effective dose of an anti-platelet derived growth factor (PDGF) beta receptor antibody.

~~23.~~ A method according to claim ~~22~~, wherein said antibody inhibits one or more intimal hyperplastic processes selected from the group consisting of vascular smooth muscle cell proliferation and vascular smooth muscle cell migration.

4 2
~~24.~~ A method according to claim ~~22~~, wherein said antibody inhibits binding of PDGF to PDGF beta receptors.

5 ~~25.~~ A method according to claim ~~22~~, wherein said antibody is a monoclonal antibody.

6 2
~~26.~~ A method according to claim ~~22~~, wherein said antibody is administered concurrently with, or within a therapeutically effective time period before an occurrence of acute vascular injury.

7 6
~~27.~~ A method according to claim ~~26~~, wherein said injury is due to angioplasty, atherectomy or other invasive methods of plaque removal.

8 2
~~28.~~ A method according to claim ~~22~~, wherein said antibody is administered within a therapeutically effective time period following an occurrence of acute vascular injury.

9 3
~~29.~~ A method according to claim ~~28~~, wherein said injury is due to angioplasty, atherectomy or other invasive methods of plaque removal.

10 2
~~30.~~ A method according to claim ~~22~~, wherein said antibody is administered concurrently with, or within a therapeutically effective time period before, emplacement of a vascular graft or transplanted organ.

11 2
~~31.~~ A method according to claim ~~22~~, wherein said antibody is administered within a therapeutically effective time period following emplacement of a vascular graft or transplanted organ.

12 2
~~32.~~ A method according to claim ~~22~~, wherein one or more anti-PDGF beta receptor antibodies is administered to said mammal.

13 2
~~33.~~ A method according to claim ~~22~~, wherein said antibody is a humanized monoclonal antibody.

14 2
~~34.~~ A method according to claim ~~22~~, wherein said antibody is a single chain antibody.

Cancel

15 2
~~35.~~ A method according to claim ~~22~~, wherein said antibody is a chimeric antibody.

16 5
~~36.~~ A method according to claim ~~35~~, wherein said antibody is a human-mouse chimeric antibody.

17 6
~~37.~~ A method according to claim ~~36~~, wherein said chimeric antibody comprises mouse variable domains operably linked to human constant domains.

~~38.~~ A method according to any one of claims 17, 21 or 22, wherein the antibody is MAb 2A1E2.

Cancel

REMARKS

Applicants respectfully request that the Examiner enter and consider the foregoing preliminary amendment upon initial consideration on the merits of the present application. Claims 17 and 19-20 correspond to allowed claims 102-104 which were canceled without